Amphetamine exposure is elevated in Parkinson's disease

NeuroToxicology

Volumn 27, Issue 6, 2006, Pages 1003-1006

  Garwood, Elisabeth R ^a   Bekele, Wosen ^b   McCulloch, Charles E ^c   Christine, Chadwick W ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amphetamine; Amyotrophic lateral sclerosis; Neuropathy; Parkinson's disease; Stimulant

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; METHAMPHETAMINE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTHMA; CAREGIVER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG ABUSE; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; DRUG USE; FACULTY PRACTICE; FEMALE; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; NOSE CONGESTION; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SPOUSE; STATISTICAL SIGNIFICANCE; TELEPHONE; WEIGHT REDUCTION;

ADRENERGIC AGENTS; AGED; AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; AMYOTROPHIC LATERAL SCLEROSIS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; TELEPHONE;

EID: 33751506062     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2006.03.015     Document Type: Article

References (17)

1. Brooks B.R., Miller R.G., Swash M., and Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000) 293-299
2. Brown J.M., and Yamamoto B.K. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther 99 (2003) 45-53
3. Davidson C., Gow A.J., Lee T.H., and Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36 (2001) 1-22
4. Di Monte D.A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurol 2 (2003) 531-538
5. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
6. Garwood E.R., McCulloch C.R., and Christine CW. Amphetamine exposure is elevated in ALS, PD and peripheral neuropathy patients. Neurology 62 Suppl 5 (2004) A213 Abstract
7. Gelb D.J., Oliver E., and Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 56 (1999) 33-39
8. Guilarte T.R. Is methamphetamine abuse a risk factor in parkinsonism?. Neurotoxicology 22 (2001) 725-731
9. Harrison L, Hughes A. The validity of self-reported drug use: improving the accuracy of survey estimate. NIH publication 97-4147. NIDA research Monograph no 167. Washington: Government Printing Office; 1997.
10. McCann U.D., Wong D.F., Yokoi F., Villemagne V., Dannals R.F., and Ricaurte G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35 428. J Neurosci 18 (1998) 8417-8422
11. Moszczynska A., Fitzmaurice P., Ang L., et al. Why is parkinsonism not a feature of human methamphetamine users?. Brain 127 (2004) 363-370
12. Office of Applied Studies. National household survey on drug abuse: main findings. (DHHS publication No SMA 00-3381) Rockville, MD 2000: substance abuse and mental health services administration, 1998. p. 32.
13. Parkes J.D., Tarsy D., Marsden C.D., et al. Amphetamines in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 38 (1975) 232-237
14. Sotnikova TD, Beaulieu J, Barak LS, Wetsel WC, Caron MG, Gainetdinov RG. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease PLoS Biol. 2005;3:e271.
15. Tanner C.M., Ottman R., Goldman S.M., et al. Parkinson disease in twins: an etiologic study. JAMA 281 (1999) 341-346
16. Wilson J.M., Kalasinsky K.S., Levey A.I., et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2 (1996) 699-703
17. Wirdefeldt K., Gatz M., Schalling M., and Pedersen N.L. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 63 (2004) 305-311